Atlas Trials

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Clinical trial NCT05623267 · RECRUITING

Trial details

NCT number
NCT05623267
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Limited Stage Small Cell Lung Cancer
Start date
2023-07-01
Primary completion
2025-12-31
Enrollment
346

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.